Home » FightingDrugFailure » Partner Sites » Department of Pharmacology, University of Liverpool » Scientific and Professional Expertise

Pharmacogenomics Projects

  • Non-steroidal anti-inflammatory induced peptic ulceration
  • Pharmacogenetics of Acute Coronary Syndrome
  • A Pharmacogenomic study of steroid-induced hypothalamic-pituitary-adrenal (HPA) axis suppression in children with asthma
  • Molecular genetics of idiosyncratic adverse drug reactions
  • An investigation of the chemical and cellular basis of drug hypersensitivity
  • Variability in response to Warfarin
  • Pharmacogenetics of drug induced liver injury
  • Prediction of response to Tamoxifen in breast cancer
  • Clostridium difficile associated toxin disease
  • Penicillin allergy development of a novel predictive and diagnostic test
  • Cell archive of HLA-typed healthy volunteers
  • Drug safety in HIV disease: focus on HAART related lipodystrophy
  • Molecular genetics of Adverse Drug Reactions
  • Pharmacogenetics of statin-induced myopathy
  • Molecular genetics of Adverse Drug Reactions
  • Biomarkers of paracetamol-induced liver injury
  • Biomarkers of renal injury in preterm infants
  • Biomarkers of bleomycin - induced lung toxicity in testicular cancer patients
  • Paediatric warfarin study
  • Pharmacogenetics of anticoagulant therapy - a randomised controlled trial
  • Pharmacogenetics of methadone dose requirements
  • TAILOR-an adaptive trial to evaluate the role of telmisartan in ameliorating insulin resistance in HIV-positive individuals

Scientific and Professional Expertise

Professor Pirmohamed is leading a multi-disciplinary team comprising scientists, clinicians and nurses in identifying genes and pathways which dictate a patient’s positive or negative response to a drug.  This team collaborates with researchers locally, regionally, nationally and internationally to identify genetic predisposing factors for drug responses associated with a number of disease areas including epilepsy, acute coronary syndrome and asthma.

Professor Pirmohamed: "The study of pharmacogenetics is vital to the public health of this country.  An area of particular importance may be drug safety.  One of our recent studies showed that at any one time the equivalent of more than seven 800-bed hospitals are taken up with the patients who have suffered the side effects of drugs they have been prescribed."  A quarter of a million people are admitted to hospital in the UK each year following adverse reactions to a variety of commonly prescribed drugs which costs the NHS an average of £466 million annually (Pirmohamed, et al. 2004).

Various important areas are being tackled as part of the pharmacogenetics research programme in Liverpool (click here for our projects). We are also undertaking clinical trials to demonstrate the clinical utility of pharmacogenetic tests, for example, a trial of genotype guided dosing for warfarin (EU-PACT). The concerted effort together with the critical mass of expertise will allow us to provide the evidence base for pharmacogenetics that is necessary to revolutionise the way important illnesses are treated in the UK and worldwide in a number of important diseases areas.